|1.||Lampidis, Theodore J: 21 articles (09/2015 - 12/2002)|
|2.||Oriuchi, Noboru: 15 articles (02/2014 - 01/2003)|
|3.||Kaira, Kyoichi: 13 articles (02/2014 - 11/2007)|
|4.||Kurtoglu, Metin: 12 articles (02/2014 - 12/2006)|
|5.||Spitz, Douglas R: 11 articles (01/2015 - 02/2006)|
|6.||Dwarakanath, B S: 11 articles (01/2013 - 12/2004)|
|7.||Nakajima, Takashi: 10 articles (02/2014 - 11/2007)|
|8.||Yamamoto, Nobuyuki: 9 articles (02/2014 - 08/2010)|
|9.||Higuchi, Tetsuya: 9 articles (01/2014 - 02/2004)|
|10.||Endo, Keigo: 9 articles (04/2009 - 01/2003)|
04/10/1977 - "Under conditions of 2-deoxyglucose inhibition, the nonglycosylated form of K-46 light chain constitutes a significantly greater proportion of accumulated intracellular protein, suggesting that the biosynthesis of the polypeptide chain of K-46 light chain proceeds at a nearly normal rate, but that the absence of the carbohydrate side chain of the protein retards, but does not prevent, the intracellular transport of the protein and its export from the tumor cell."
12/15/2012 - "While the anti-tumor efficacy of 2-deoxy-D-glucose (2-DG) is normally low in monotherapy, it may represent a valuable radio- and chemo-sensitizing agent. "
02/01/1987 - "These results suggest that a small dose of 2-deoxy-D-glucose shows considerable promise in specific inhibition of fibroblastic proliferation during the process of establishing the cell line of the cancer."
05/01/2006 - "A nonradioactive fluorescent deoxyglucose analogue may have many applications for both imaging of tumors and monitoring therapeutic efficacy of drugs in living animals and may eventually translate to clinical applications. "
11/20/2014 - "2-[(18)F]fluoro-2-deoxy-d-glucose ((18)FDG) is a tumor diagnostic radiotracer of great importance in both diagnosing primary and metastatic tumors and in monitoring the efficacy of the treatment. "
01/01/2000 - "Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography--a study evaluating [18F]Fluoro-2-deoxy-D-glucose."
09/01/1999 - "The purpose of this study was to examine the effects of hypoxia and muscle contractions on rates of 2-deoxyglucose (2-DG) transport in red and white portions of the gastrocnemius muscle of the rat. "
10/01/2015 - "These include a rapid increase in the use of magnetic resonance imaging, development of contrast-enhanced imaging techniques, integration of fluorinated deoxyglucose-positron emission tomography, evaluation of hypoxia imaging techniques, and numerous others. "
05/01/2014 - "Moreover, NDRG2 overexpression also enhanced the pro-apoptotic effects of 2-deoxyglucose (2-DG) or hypoxia, an inducer of metabolic stresses. "
01/01/2014 - "However, deoxyglucose greatly increased the neuronal death induced by hypoxia. "
07/01/2006 - "Positron emission tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) is useful in the management of lymphomas. "
06/01/2012 - "This study evaluates the utility of positron emission tomography/computed tomography using 2-[18F]fluoro-2-deoxyglucose for this purpose and in situations with suspected lymphoma relapse. "
11/01/2008 - "The aim of this study was to evaluate the diagnostic accuracy of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) for staging/restaging, evaluating the treatment response, and screening of recurrence in patients with malignant lymphoma (ML) during long-term follow-up, and to compare that with computer tomography (CT)/magnetic resonance imaging (MRI). "
11/01/2015 - "To determine whether combined 2-[(18)F]-fluoro-2-deoxy-d-glucose ((18)F-FDG) positron-emission tomography (PET)/computed tomography (CT) and diffusion-weighted imaging (DWI) can be used for characterisation of different lymphoma subtypes, i.e., indolent versus aggressive lymphoma, and also to assess the prognostic value of different quantitative parameters of whole-body (WB) DWI and (18)F-FDG PET/CT. "
06/01/2015 - "To determine the value of diffusion-weighted MRI (DWI-MRI) for treatment response assessment in 2-[18F]fluoro-2-deoxy-D-glucose (FDG)-avid lymphoma. "
04/01/1988 - "Because previous studies showed that bilateral lesions of the suprachiasmatic nucleus (SCN) eliminated hyperglycemia induced by intracranial injection of 2-deoxy-D-glucose and that blinding largely suppressed the hyperglycemia, the effects of these two treatments on hyperglycemia induced by electrical stimulation of the LPBD were examined. "
01/01/1996 - "Because the hyperglycemia due to 2-deoxy-D-glucose was shown to be dependent on the functions of the adrenal medulla and sympathetic nervous system, the effect of bilateral lesions of the suprachiasmatic nucleus on changes in the nervous activity of sympathetic efferents to the adrenal after intracranial injection of 2-deoxy-D-glucose was examined in rats. "
12/05/1994 - "Increase of hypothalamic cholinergic activity in 2-deoxyglucose hyperglycemia."
11/28/1994 - "Hypothalamic cholinergic and noradrenergic neurons in hyperglycemia induced by 2-deoxyglucose."
03/01/1990 - "Adrenodemedullation suppressed the hyperglycemia but not the plasma FFA increase induced by intraventricular 2-deoxyglucose. "
|5.||Hodgkin Disease (Hodgkin's Disease)
08/01/2011 - "A 28-year-old man with a history of Hodgkin lymphoma that was intensely [F-18]fluoro-2-deoxy-D-glucose-avid at diagnosis had achieved complete remission following appropriate therapy. "
06/01/2014 - "Fluoro-deoxyglucose positron emmission tomography combined with computed tomography (FDG-PET/CT) is superior to iliac bone marrow biopsy (iBMB) for detection of bone marrow involvement (BMI) in staging of Hodgkin's lymphoma (HL). "
09/01/2011 - "Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy."
08/20/2007 - "Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study."
12/28/2013 - "To assess the prognostic value and risk classification improvement of metabolic staging (MS) with Initial 2-[18F]-fluoro-2-desoxy-D-glucose positron emission tomography (FDG-PET) in initial staging of Hodgkin's Lymphoma (HL) patients to predict 5 years overall survival (5y-OS) and event free survival (EFS). "
|5.||Adenosine Triphosphate (ATP)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)